Newly Approved Meds Rarely Used for Sickle Cell Disease
Hydroxyurea used by 24.6 percent with sickle cell disease, while l-glutamine, voxelotor, crizanlizumab were used by 2.0, 1.9, and 1.4 percent
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.